Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Paul Black’s 3 thumb rules for identifying great wealth creators
Veteran portfolio manager Paul Black’s investment framework focuses on identifying businesses with competitive advantages that strengthen over time. His three key rules emphasise widening moats,